312 related articles for article (PubMed ID: 23517433)
1. Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients.
Strollo F; Strollo G; Morè M; Magni P; Macchi C; Masini MA; Carucci I; Celotti F; Ruscica M; Gentile S
Aging Male; 2013 Jun; 16(2):33-7. PubMed ID: 23517433
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
3. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
4. Testosterone replacement therapy improves insulin sensitivity and decreases high sensitivity C-reactive protein levels in hypogonadotropic hypogonadal young male patients.
Wu XY; Mao JF; Lu SY; Zhang Q; Shi YF
Chin Med J (Engl); 2009 Dec; 122(23):2846-50. PubMed ID: 20092788
[TBL] [Abstract][Full Text] [Related]
5. Assessment of possible effects for testosterone replacement therapy in men with symptomatic late-onset hypogonadism.
Yamaguchi K; Ishikawa T; Chiba K; Fujisawa M
Andrologia; 2011 Feb; 43(1):52-6. PubMed ID: 21219383
[TBL] [Abstract][Full Text] [Related]
6. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
Morrison BF; Reid M; Madden W; Burnett AL
Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
8. Improved Lower Urinary Tract Symptoms Associated With Testosterone Replacement Therapy in Japanese Men With Late-Onset Hypogonadism.
Okada K; Miyake H; Ishida T; Sumii K; Enatsu N; Chiba K; Matsushita K; Fujisawa M
Am J Mens Health; 2018 Sep; 12(5):1403-1408. PubMed ID: 27256990
[TBL] [Abstract][Full Text] [Related]
9. Change in cytokine levels after administration of saikokaryuukotsuboreito or testosterone in patients with symptoms of late-onset hypogonadism.
Tsujimura A; Miyagawa Y; Okuda H; Yamamoto K; Fukuhara S; Nakayama J; Takao T; Nonomura N; Okuyama A
Aging Male; 2011 Mar; 14(1):76-81. PubMed ID: 20712429
[TBL] [Abstract][Full Text] [Related]
10. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study.
Legros JJ; Meuleman EJ; Elbers JM; Geurts TB; Kaspers MJ; Bouloux PM;
Eur J Endocrinol; 2009 May; 160(5):821-31. PubMed ID: 19211706
[TBL] [Abstract][Full Text] [Related]
11. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.
Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N;
J Clin Endocrinol Metab; 2000 Aug; 85(8):2839-53. PubMed ID: 10946892
[TBL] [Abstract][Full Text] [Related]
12. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
Stephenson K; Neuenschwander PF; Kurdowska AK
Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
[TBL] [Abstract][Full Text] [Related]
13. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
14. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
[TBL] [Abstract][Full Text] [Related]
15. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
[TBL] [Abstract][Full Text] [Related]
16. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
17. [Role of androgen in the elderly. Clinical androgen replacement therapy for late-onset hypogonadism].
Amano T
Clin Calcium; 2013 Aug; 23(8):1179-84. PubMed ID: 23892219
[TBL] [Abstract][Full Text] [Related]
18. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study.
Bouloux PM; Legros JJ; Elbers JM; Geurts TB; Kaspers MJ; Meehan AG; Meuleman EJ;
Aging Male; 2013 Jun; 16(2):38-47. PubMed ID: 23581697
[TBL] [Abstract][Full Text] [Related]
19. Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism.
Liao CH; Wu YN; Lin FY; Tsai WK; Liu SP; Chiang HS
Andrology; 2013 Jul; 1(4):563-9. PubMed ID: 23653307
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy of testosterone ointment (Glowmin) treatment for late-onset-hypogonadism (LOH) patients according to LOH severity].
Amano T; Imao T; Takemae K; Iwamoto T; Baba K; Yamakawa K; Nakazawa R; Yoshida K; Sugimori H; Tanaka T; Katabami T; Tanaka M
Hinyokika Kiyo; 2007 Jan; 53(1):25-9; discussion 29. PubMed ID: 17310765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
